Chimeric Therapeutics (ASX: CHM) COO Jennifer Chow joined Steve Darling from Proactive to confirm that all patients dosed in the first patient cohort in City of Hope’s phase 1 CLTX CAR T cell clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities.
Chow telling Proactive now that this safety milestone for all patients in cohort 1 has been met, the trial will now advance to the second dosing level, which will administer CLTX CAR T cells by two routes intratumoral and intracranial intraventricular.